Number and Type of Blood Products Are Negatively Associated With Outcomes After Cardiac Surgery.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
03 2022
Historique:
received: 29 07 2020
revised: 10 05 2021
accepted: 14 06 2021
pubmed: 1 8 2021
medline: 9 4 2022
entrez: 31 7 2021
Statut: ppublish

Résumé

The association between blood transfusion and adverse outcome is documented in cardiac surgery. However, the incremental significance of each unit transfused, whether red blood cell (RBC) or non-RBC, is uncertain. This study examined the relationship of patient outcomes with the type and number of blood product units transfused. Statewide data from 24 082 adult cardiac surgery patients were included. The relationship with blood transfusion was assessed for morbidity and 30-day mortality using total number of RBC and non-RBC units transfused, specific type of non-RBC units, and different combinations of transfusion (only RBC, only non-RBC, RBC + non-RBC). Multivariable logistic regressions examined these associations. Median age was 66 years (30% female patients), and 51% of patients received a transfusion (31%-66% across hospitals). Risk-adjusted analyses found each blood product unit was associated with 9%, 7%, and 4% greater odds for 30-day mortality, major morbidity, and minor morbidity, respectively (all P < .001). Odds for 30-day mortality were 13% greater with each RBC unit (P < .001) and 6% greater for each non-RBC unit (P < .001). Each unit of fresh frozen plasma (P < .001) and platelets (P < .001) increased the odds for 30-day mortality, but no effect was found for cryoprecipitate (P = .725). Odds for 30-day mortality were lower for non-RBC-only (odds ratio, 0.52; P = .030) and greater for RBC + non-RBC (odds ratio, 2.98; P < .001) compared with RBC-only transfusion. Independent of center variability on transfusion methods, each additional unit transfused was associated with increased odds for complications, with RBC transfusion carrying greater risk compared with non-RBC. Comprehensive evidence-based clinical approaches and coordination are needed to guide each blood transfusion event after cardiac surgery.

Sections du résumé

BACKGROUND
The association between blood transfusion and adverse outcome is documented in cardiac surgery. However, the incremental significance of each unit transfused, whether red blood cell (RBC) or non-RBC, is uncertain. This study examined the relationship of patient outcomes with the type and number of blood product units transfused.
METHODS
Statewide data from 24 082 adult cardiac surgery patients were included. The relationship with blood transfusion was assessed for morbidity and 30-day mortality using total number of RBC and non-RBC units transfused, specific type of non-RBC units, and different combinations of transfusion (only RBC, only non-RBC, RBC + non-RBC). Multivariable logistic regressions examined these associations.
RESULTS
Median age was 66 years (30% female patients), and 51% of patients received a transfusion (31%-66% across hospitals). Risk-adjusted analyses found each blood product unit was associated with 9%, 7%, and 4% greater odds for 30-day mortality, major morbidity, and minor morbidity, respectively (all P < .001). Odds for 30-day mortality were 13% greater with each RBC unit (P < .001) and 6% greater for each non-RBC unit (P < .001). Each unit of fresh frozen plasma (P < .001) and platelets (P < .001) increased the odds for 30-day mortality, but no effect was found for cryoprecipitate (P = .725). Odds for 30-day mortality were lower for non-RBC-only (odds ratio, 0.52; P = .030) and greater for RBC + non-RBC (odds ratio, 2.98; P < .001) compared with RBC-only transfusion.
CONCLUSIONS
Independent of center variability on transfusion methods, each additional unit transfused was associated with increased odds for complications, with RBC transfusion carrying greater risk compared with non-RBC. Comprehensive evidence-based clinical approaches and coordination are needed to guide each blood transfusion event after cardiac surgery.

Identifiants

pubmed: 34331931
pii: S0003-4975(21)01290-X
doi: 10.1016/j.athoracsur.2021.06.061
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

748-756

Informations de copyright

Copyright © 2022 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Niv Ad (N)

Thoracic and Cardiac Surgery, White Oak Medical Center, Silver Spring, Maryland; Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland. Electronic address: nivadmd14@gmail.com.

Paul S Massimiano (PS)

Thoracic and Cardiac Surgery, White Oak Medical Center, Silver Spring, Maryland.

Anthony J Rongione (AJ)

Thoracic and Cardiac Surgery, White Oak Medical Center, Silver Spring, Maryland.

Bradley Taylor (B)

Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland.

Stefano Schena (S)

Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Diane Alejo (D)

Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Clifford E Fonner (CE)

Maryland Cardiac Surgery Quality Initiative, Inc, Baltimore, Maryland.

Rawn Salenger (R)

Department of Cardiothoracic Surgery, St. Joseph Medical Center, University of Maryland, Towson, Maryland.

Glenn Whitman (G)

Division of Cardiac Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Thomas S Metkus (TS)

Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

Sari D Holmes (SD)

Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH